Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

164 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-19

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to collect real-world data on patient outcomes and evaluate the safety and performance of the Lifetech Ankura™ AAA Stent Graft System, Ankura™ Cuff Stent Graft System, Ankura™ AUI Stent Graft System and ZoeTrack™ Super Stiff Guidewire.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

E-tegra Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms

NCT02485496

Abdominal Aortic Aneurysm AAA

TERMINATED

Safety Study for the Treatment of Abdominal Aortic Aneurysms

NCT00610090

Abdominal Aortic Aneurysms

TERMINATED PHASE2

A Clinical Study to Evaluate the Safety and Performance of the Modular AAA Stent-Graft System

NCT01368679

Cardiovascular Diseases Abdominal Aortic Aneurysm

WITHDRAWN PHASE3

A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic Aneurysms

NCT00646048

Abdominal Aortic Aneurysm

COMPLETED PHASE1

Clinical Outcomes and Major Adverse Events in Patients Treated With Physician-Modified Fenestrated and Branched Stent Grafts

NCT06526676

Juxtarenal Aortic Aneurysm Pararenal Aneurysm Thoracoabdominal Aortic Aneurysm

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Abdominal aortic aneurysm (AAA) is the most common true arterial aneurysm. Surgical management options for AAA include traditional Open Surgical Repair (OSR) and minimally invasive Endovascular Aneurysm Repair (EVAR). Multiple endovascular devices are commercially available for repair of AAA. Currently available endovascular grafts for infrarenal aortic repair share a bifurcated, modular design. Ankura™ Stent Graft Systems are minimally invasive endovascular devices that offer an alternative treatment for patients with AAA, which have been marketed worldwide for many years. In order to evaluate the long-term safety and performance of the investigational device from real world, this post-market clinical follow-up study is planned under the Regulation (EU) 2017/745. The study intends to enroll 162 subjects. The anticipated enrollment period is approximately 1.5 years and subjects will be followed for 3 years (36 months) post-implantation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Aortic Aneurysm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AAA Subjects

Patient diagnosed with Abdominal Aortic Aneurysm, who needs endovascular aortic repair.

Ankura™ AAA Stent Graft System; Ankura™ Cuff Stent Graft System; Ankura™ AUI Stent Graft System

Intervention Type DEVICE

Patients will be implanted with Ankura™ AAA, Cuff or AUI Stent Graft System in accordance with the Instructions for Use (IFU).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ankura™ AAA Stent Graft System; Ankura™ Cuff Stent Graft System; Ankura™ AUI Stent Graft System

Patients will be implanted with Ankura™ AAA, Cuff or AUI Stent Graft System in accordance with the Instructions for Use (IFU).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient diagnosed with Abdominal Aortic Aneurysm (AAA), who needs endovascular aortic repair;
2. Patient's anatomy suits Ankura™ AAA and Cuff Stent Graft Systems, or AUI Stent Graft IFU requirements, which indicated by the following:

1. Adequate iliac/femoral access vessel that is compatible with the required delivery system.
2. Non-aneurysmal proximal aortic neck length ≥15mm.
3. Non-aneurysmal proximal aortic neck diameter of 18-32mm.
4. Proximal aortic neck angulation ≤ 60°.
5. Distal iliac artery anchorage zone ≥15mm.
6. Distal iliac artery diameter of i. 8-22 mm (for Ankura™ AAA and Cuff Stent Graft Systems), OR ii. 10-16 mm (for Ankura™ AUI Stent Graft System).
7. Morphology suitable for endovascular repair.
3. Patient could understand the purpose of the clinical trial, agrees to comply with the requirements of the study including the 3-year follow-up, and signed the patient informed consent, will participate in the study.

Exclusion Criteria

1. Age\<18 years or Age\>85 years;
2. Patients' life expectancy \< 1 year;
3. Pregnant or plan to be pregnant or breast feeding;
4. Patient with any contraindications mentioned in the Ankura™ AAA and Cuff Stent Graft Systems, or in Ankura™ AUI Stent Graft system IFU:

1. Patient with acute systemic infection;
2. Patient with mesenteric blood flow mainly supplied by the inferior mesenteric artery;
3. Patient with accessory renal artery original from abdominal artery;
4. Patient who has allergic reaction to the device;
5. Patient who is not suitable for endovascular repair in vascular morphology;
6. Patient who cannot tolerate contrast agents due to renal insufficiency;
7. Patient who is allergic to contrast agent;
8. Patient's aneurysms neck has thrombus;
9. Non-aneurysmal proximal aortic neck length \<15mm;
10. Non-aneurysmal proximal aortic neck diameter \<18mm or \>32mm;
11. Proximal aortic neck angulation \> 60°;
12. Distal iliac artery anchorage zone \<15mm;
13. Distal iliac artery diameter: i. For Ankura™ AAA and Cuff Stent Graft Systems: \<8mm or \>22mm, OR ii. For Ankura™ AUI Stent Graft system: \<10mm or \>16mm.
5. Patient with traumatic aortic injury;
6. Patient with uncorrectable coagulopathy;
7. Patient with hereditary connective tissue disease, including but not limited to Marfan Syndrome or Ehlers-Danlos Syndrome;
8. Patient with concomitant thoracic aortic or thoraco-abdominal aneurysms；
9. Patient who weighs greater than 350 pounds (150kg) or cannot undergo accurate fluoroscopy examination due to obesity.
10. Acute myocardial infarction or heart failure (NYHA class III and IV), respiratory failure, malignant tumor and other serious systemic diseases.
11. Subject must not be participating in another study for an investigational drug and/or device that may clinically interfere with this study's endpoints.
12. Any condition (medical or anatomic) which makes the patient not suitable for endovascular repair according to the opinion of the investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No